Analytical Data
-
基因名
cGB-PDE
-
简介
cGB-PDE protein regulates signal transduction by specifically hydrolyzing cto 5'-GMP, thereby controlling the intracellular concentration of cyclic nucleotides, particularly nitric-oxide-generated cGMP. cGB-PDE Protein, Mouse (Myc, His) is the recombinant mouse-derived cGB-PDE protein, expressed by E. coli , with N-His, C-Myc labeled tag.
- Application
-
别名
Pde5a; Pde5; cGMP-specific 3',5'-cyclic phosphodiesterase; EC 3.1.4.35; cGMP-binding cGMP-specific phosphodiesterase; CGB-PDE
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His;C-Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8CG03
-
表达区间
D154-N320
-
蛋白长度
Partial
-
分子量
29 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclic guanosine monophosphate phosphodiesterase (cGB-PDE) is an enzyme that plays a crucial role in the regulation of intracellular levels of cyclic guanosine monophosphate (cGMP), a second messenger involved in various physiological processes, including vasodilation, neuronal signaling, and cell growth. The study of cGB-PDE has gained significant attention due to its potential implications in cardiovascular diseases, neurological disorders, and cancer. Abnormal cGMP signaling often indicates pathological conditions, making cGB-PDE a promising target for therapeutic interventions. Recent advancements in structural biology, particularly in recombinant protein technology, have enabled researchers to produce functional cGB-PDE proteins for detailed biochemical characterization and structure-function studies. This recombinant approach allows for the exploration of cGB-PDE's catalytic mechanisms, regulation, and interactions with other cellular components. Furthermore, understanding the molecular dynamics of cGB-PDE may provide insights into its role in drug development, enabling the design of selective inhibitors or activators for specific therapeutic applications. Ongoing research aims to elucidate the regulatory pathways involving cGB-PDE, thereby contributing to the development of innovative strategies for treating diseases associated with cGMP dysregulation. In summary, the investigation into recombinant cGB-PDE proteins offers a promising avenue for advancing our understanding of cGMP signaling and its therapeutic potential, highlighting the importance of this enzyme in both basic and applied biomedical research.
